Literature DB >> 12172093

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

Mounir Ait-Khaled1, Chris Stone, Gillian Amphlett, Bonaventura Clotet, Schlomo Staszewski, Christine Katlama, Margaret Tisdale.   

Abstract

The resistance of HIV clinical isolates with or without M184V was analysed in relation to plasma HIV-1-RNA level and time on therapy. The number of thymidine analogue mutations (TAMs) was lower in isolates with M184V, this was independent of plasma HIV-1-RNA level and time on therapy for T215F/Y, D67N and L210W. This suggests a direct effect of M184V on the reduced selection of TAMs. Lamivudine use was significantly associated with lower median fold resistance to zidovudine and stavudine.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12172093     DOI： 10.1097/00002030-200208160-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

Review 1.  Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Mark A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 2.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Authors:  Diane N Singhroy; Mark A Wainberg; Thibault Mesplède
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

4.  Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Authors:  André F A Santos; Denis M Tebit; Matthew S Lalonde; Ana B Abecasis; Annette Ratcliff; Ricardo J Camacho; Ricardo S Diaz; Ottmar Herchenröder; Marcelo A Soares; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.

Authors:  D T Dunn; R L Goodall; P Munderi; C Kityo; M Ranopa; L Bacheler; M Van Houtte; C Gilks; P Kaleebu; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Authors:  Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

7.  Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.

Authors:  Yudong Quan; Bluma G Brenner; Maureen Oliveira; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.

Authors:  Chris Stone; Mounir Ait-Khaled; Charles Craig; Philip Griffin; Margaret Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Authors:  L L Ross; E Rouse; P Gerondelis; E DeJesus; C Cohen; J Horton; B Ha; E R Lanier; R Elion
Journal:  J Antimicrob Chemother       Date:  2009-12-15       Impact factor: 5.790

10.  Modelling imperfect adherence to HIV induction therapy.

Authors:  Rachelle E Miron; Robert J Smith
Journal:  BMC Infect Dis       Date:  2010-01-12       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.